Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LNG Energy Announces Signing of Hydrocarbon Productive Participation Contracts (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioCryst Pharmaceuticals Inc BCRX

Healthcare Biotechnology
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of... see more

Recent & Breaking News (NDAQ:BCRX)

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire August 3, 2021

BioCryst Appoints Vincent Milano to Board of Directors

GlobeNewswire July 28, 2021

BioCryst to Report Second Quarter 2021 Financial Results on August 5

GlobeNewswire July 22, 2021

BioCryst Reports First Quarter 2021 Financial Results and Upcoming Key Milestones

GlobeNewswire May 6, 2021

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 2, 2020

BioCryst Announces RAPIVAB® (peramivir injection) and Galidesivir Presentations at IDWeek 2017™

GlobeNewswire October 4, 2017

18 Stocks Moving In Thursday's Pre-Market Session

Benzinga.com  September 21, 2017

BioCryst’s RAPIVAB® (peramivir injection) Receives FDA Approval for a Pediatric Indication

GlobeNewswire September 21, 2017

BioCryst Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares and Completion of Public Offering of Common Stock

GlobeNewswire September 15, 2017

BioCryst Pharmaceuticals Prices Public Offering of Common Stock

GlobeNewswire September 12, 2017

10 Biggest Mid-Day Losers For Thursday

Benzinga.com  September 12, 2017

Mid-Day Market Update: Advaxis Drops Following Q3 Results; Aethlon Medical Shares Climb

Benzinga.com  September 12, 2017

5 Stocks To Watch For September 12, 2017

Benzinga.com  September 12, 2017

BioCryst Pharmaceuticals Commences Public Offering of Common Stock

GlobeNewswire September 11, 2017

Technical Snapshots for These Biotech Stocks -- Alnylam Pharma, Alexion Pharma, Albany Molecular Research, and BioCryst Pharma

PR Newswire September 8, 2017

Mid-Afternoon Market Update: NCI Building Drops On Downbeat Results; GoPro Shares Spike Higher

Benzinga.com  September 7, 2017

25 Stocks Moving In Wednesday's Pre-Market Session

Benzinga.com  September 6, 2017

BioCryst Announces Positive Results from its APeX-1 Phase 2 Trial in HAE

GlobeNewswire September 5, 2017

BioCryst Announces Corporate Update Conference Call and Webcast

GlobeNewswire September 4, 2017

BioCryst to Present at Three Upcoming Investor Conferences

GlobeNewswire August 23, 2017